Last10K.com

Bristol Myers Squibb Co (BMY) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Bristol Myers Squibb Co

HISTORY TOOLS
CIK: 319126 Ticker: BMY


Exhibit 99.1
bmslogoq22017a01.jpg

Bristol-Myers Squibb Reports Third Quarter Financial Results

•
Increases Third Quarter Revenues 8% to $5.7 Billion
•
Posts Third Quarter GAAP EPS of $1.16 and Non-GAAP EPS of $1.09
•
Presents Important New Clinical Data on Novel, Oral, Selective TYK2 Inhibitor for Potential Treatment of Patients with Moderate to Severe Plaque Psoriasis
•
Additional Opdivo Approvals Including for Adjuvant Treatment of Adult Patients with Melanoma in the European Union
•
Updates on Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer
•
Updates 2018 GAAP and Non-GAAP EPS Guidance

(NEW YORK, October 25, 2018)
 - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key regulatory and clinical milestones across the portfolio.

“We had a very good quarter with strong commercial performance and advances in our portfolio through important clinical and regulatory milestones, including exciting new data for psoriasis patients with our internally discovered and developed TYK2 inhibitor,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “Looking forward, we will continue to deliver on our strategy through robust commercial execution and advancing the potential of our increasingly diverse R&D pipeline.”

 
Third Quarter
$ amounts in millions, except per share amounts
 
 
 
 
 
 
2018
 
2017
 
Change
Total Revenues
$
5,691

 
$
5,254

 
8
%
GAAP Diluted EPS
1.16

 
0.51

 
**

Non-GAAP Diluted EPS
1.09

 
0.75

 
45
%
** In excess of +/- 100%





1

The following information was filed by Bristol Myers Squibb Co (BMY) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Bristol Myers Squibb Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bristol Myers Squibb Co.

Continue

Assess how Bristol Myers Squibb Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bristol Myers Squibb Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
M & A
Other
Filter Subcategory:
All
Product
Expense
Cash Flow
Geography
Dividend
Income
Other
Inside Bristol Myers Squibb Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (Unaudited)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Comprehensive Income (Unaudited)
Consolidated Statements Of Earnings (Unaudited)
Accrued Liabilities
Accrued Liabilities (Details)
Accrued Liabilities (Tables)
Alliances
Alliances (Details)
Alliances (Tables)
Basis Of Presentation (New Accounting Pronouncements) (Details)
Basis Of Presentation (Policies)
Basis Of Presentation And Recently Issued Accounting Standards (Notes)
Basis Of Presentation Recently Adopted Accounting Standards (Tables)
Business Segment Information
Divestitures (Details)
Divestitures (Notes)
Divestitures Divestitures (Tables)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Equity
Equity (Changes In Equity) (Details)
Equity (Other Comprehensive Income/(Loss)) (Details)
Equity (Tables)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Fair Value Measurement) (Details)
Financial Instruments And Fair Value Measurements (Available-For-Sale) (Details)
Financial Instruments And Fair Value Measurements (Debt) (Details)
Financial Instruments And Fair Value Measurements (Derivatives And Hedging) (Details)
Financial Instruments And Fair Value Measurements (Tables)
Goodwill And Other Intangible Assets (Details)
Goodwill And Other Intangible Assets (Tables)
Income Taxes
Income Taxes (Details)
Income Taxes (Tables)
Inventories
Inventories (Details)
Inventories (Tables)
Legal Proceedings And Contingencies
Legal Proceedings And Contingencies (Details)
Other Income (Net)
Other Income (Net) (Details)
Other Income (Net) (Tables)
Other Intangible Assets
Pension And Postretirement Benefit Plans
Pension And Postretirement Benefit Plans (Details)
Pension And Postretirement Benefit Plans (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Receivables
Receivables (Details)
Receivables (Tables)
Restructuring
Restructuring (Details)
Restructuring (Tables)
Revenue Recognition (Tables)
Revenue Recognition Disaggregation Of Revenue (Details)
Revenue Recognition Revenue Recognition (Notes)
Ticker: BMY
CIK: 14272
Form Type: 10-Q Quarterly Report
Accession Number: 0000014272-18-000197
Submitted to the SEC: Thu Oct 25 2018 11:36:04 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/bmy/0000014272-18-000197.htm